StockPriceToday

Ascendis Pharma A/S (ASND)

ASND stock price

Ascendis Pharma A/S is a biotechnology company developing prodrug therapies for endocrinology and other therapeutic areas.

About Ascendis Pharma A/S

Ascendis Pharma A/S operates as a biotechnology company focused on developing innovative prodrug therapies for endocrinology, oncology, and other therapeutic areas using its proprietary TransCon technology platform. The company's prodrug approach makes ASND stock price sensitive to clinical trial results and regulatory developments in hormone therapy and specialized medicine.

The company's TransCon technology enables development of prodrugs that provide sustained and controlled release of active therapeutics, potentially improving treatment outcomes while reducing dosing frequency. Ascendis's pipeline includes programs for growth hormone deficiency, oncology, and other conditions.

ASND stock price benefits from the company's commercial success with approved endocrinology products and its expanding pipeline of prodrug therapeutics addressing various medical conditions. The company's technology platform provides opportunities for multiple product development across different therapeutic areas.

Ascendis Pharma's partnerships with pharmaceutical companies and its prodrug expertise position the company to capitalize on growing demand for sustained-release therapeutics and improved treatment adherence. The company's global development capabilities and regulatory relationships support ASND stock price growth potential as prodrug technology gains acceptance for addressing various therapeutic challenges.

ASND Stock 12 Month Chart


Latest News for ASND

Ascendis Pharma A/S (NASDAQ:ASND) reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched ...

Ascendis Pharma A/S reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales was EUR 369.66 million compared to EUR ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.